Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Metalloproteinases and Recurrent Corneal Erosion Syndrome (MERCURE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02891694
Recruitment Status : Completed
First Posted : September 7, 2016
Last Update Posted : December 10, 2020
Sponsor:
Information provided by (Responsible Party):
Fondation Ophtalmologique Adolphe de Rothschild

Brief Summary:

Recurrent corneal erosion (RCE) syndrome can be observed either in the context of a dystrophy of the basement membrane or following corneal trauma. This syndrome is characterized by recurrent episodes of ocular pain more or less associated with localized separations between the outer epithelium and the epithelial basal lamina (basement membrane) because of anchorage abnormalities between these two corneal layers. This could be the result of an increased expression of metalloproteinases cleaving the hemidesmosomes which anchor epithelium to the basement membrane.

The investigators hypothesis is that episodes of RCEs are favored by a hyper- expression of matricial metalloprotease 9 (MMP-9) induced by EMMPRIN and Galectin-3. The identification of such induction could lead to development of therapeutics inhibiting EMMPRIN and Galectin- 3 in the RCE syndrome.


Condition or disease Intervention/treatment
Recurrent Corneal Erosion Syndrome Other: in vitro immuno-histo-chemical analysis of corneal epithelium

Layout table for study information
Study Type : Observational
Actual Enrollment : 19 participants
Observational Model: Other
Time Perspective: Cross-Sectional
Actual Study Start Date : December 2, 2016
Actual Primary Completion Date : June 26, 2020
Actual Study Completion Date : November 26, 2020

Group/Cohort Intervention/treatment
recurrent corneal erosion Other: in vitro immuno-histo-chemical analysis of corneal epithelium
control patients (refractive surgery) Other: in vitro immuno-histo-chemical analysis of corneal epithelium



Primary Outcome Measures :
  1. expression of the Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) in epithelial cells [ Time Frame: baseline ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Recurrent Corneal Erosion Syndrome and control patients (undergoing photorefractive surgical keratectomy)
Criteria

Inclusion Criteria:

  • Age > 18 years old
  • Recurrent Corneal Erosion Syndrome, with - failure of medical treatment and therapeutic photokeratectomy scheduled
  • Photorefractive surgical keratectomy (control patients)

Exclusion Criteria:

  • Opposition to participation in the study
  • Known pregnancy or breast-feeding patient
  • No medical insurance coverage

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02891694


Locations
Layout table for location information
France
Fondation Opthalmologique A de Rothschild
Paris, France, 75019
Sponsors and Collaborators
Fondation Ophtalmologique Adolphe de Rothschild
Investigators
Layout table for investigator information
Principal Investigator: Eric GABISON, MD, PhD Fondation OPH A de Rothschild
Layout table for additonal information
Responsible Party: Fondation Ophtalmologique Adolphe de Rothschild
ClinicalTrials.gov Identifier: NCT02891694    
Other Study ID Numbers: EGN_2016_8
First Posted: September 7, 2016    Key Record Dates
Last Update Posted: December 10, 2020
Last Verified: December 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Disease
Pathologic Processes